AVM Biotechnology Overview
- Year Founded
-
2008
- Status
-
Private
- Employees
-
6
- Latest Deal Type
-
M&A
- (Announced)
- Financing Rounds
-
18
AVM Biotechnology General Information
Description
Developer of small molecule therapeutics designed to treat blood cancers and solid tumors through targeted oncology treatment. The company offers a clinical-stage therapeutic candidate with pan-cancer activity, low toxicity characteristics, and expanded access treatment applications, enabling cancer patients and healthcare providers to access lower side-effect treatment options for a broad range of cancer indications.
Contact Information
Website
www.avmbiotech.comCorporate Office
- 1700 7th Avenue
- Suite 2100
- Seattle, WA 98109
- United States
Corporate Office
- 1700 7th Avenue
- Suite 2100
- Seattle, WA 98109
- United States
AVM Biotechnology Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
AVM Biotechnology Comparisons
Industry
Financing
Details
AVM Biotechnology Competitors (37)
One of AVM Biotechnology’s 37 competitors is Aura Biosciences, a Formerly VC-backed company based in Boston, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Aura Biosciences | Formerly VC-backed | Boston, MA | ||||
| Voyager Therapeutics | Formerly VC-backed | Lexington, MA | ||||
| Mesoblast | Corporation | Melbourne, Australia | ||||
| BioCardia | Formerly VC-backed | Sunnyvale, CA | ||||
| Cellaion | Formerly VC-backed | Mont-Saint-Guibert, Belgium |
AVM Biotechnology Patents
AVM Biotechnology Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3229529-A1 | Lymphocyte population and methods for producing same | Pending | 01-Sep-2021 | ||
| EP-4395784-A1 | Lymphocyte population and methods for producing same | Pending | 01-Sep-2021 | ||
| US-20240358829-A1 | Lymphocyte population and methods for producing same | Pending | 01-Sep-2021 | ||
| WO-2023034377-A1 | Lymphocyte population and methods for producing same | Inactive | 01-Sep-2021 | ||
| AU-2020451285-A1 | Methods of treatment using icam-modulating agents | Inactive | 01-Jun-2020 | A61K31/573 |
AVM Biotechnology Signals
AVM Biotechnology Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
AVM Biotechnology FAQs
-
When was AVM Biotechnology founded?
AVM Biotechnology was founded in 2008.
-
Where is AVM Biotechnology headquartered?
AVM Biotechnology is headquartered in Seattle, WA.
-
What is the size of AVM Biotechnology?
AVM Biotechnology has 6 total employees.
-
What industry is AVM Biotechnology in?
AVM Biotechnology’s primary industry is Drug Discovery.
-
Is AVM Biotechnology a private or public company?
AVM Biotechnology is a Private company.
-
What is the current valuation of AVM Biotechnology?
The current valuation of AVM Biotechnology is .
-
What is AVM Biotechnology’s current revenue?
The current revenue for AVM Biotechnology is .
-
How much funding has AVM Biotechnology raised over time?
AVM Biotechnology has raised $16.1M.
-
Who are AVM Biotechnology’s investors?
Life Science Washington Institute, Small Business Innovation Research and Small Business Technology Transfer Programs, National Cancer Institute, National Institute of Diabetes and Digestive and Kidney Diseases, and National Institutes of Health are 5 of 7 investors who have invested in AVM Biotechnology.
-
Who are AVM Biotechnology’s competitors?
Aura Biosciences, Voyager Therapeutics, Mesoblast, BioCardia, and Cellaion are some of the 37 competitors of AVM Biotechnology.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process